Amgen (AMGN) Debt-to-Equity

: 10.37 (As of Dec. 2023)

View and export this data going back to 1983. Start your Free Trial

Amgen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,443 Mil. Amgen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $63,170 Mil. Amgen's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $6,232 Mil. Amgen's debt to equity for the quarter that ended in Dec. 2023 was 10.37.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Amgen's Debt-to-Equity or its related term are showing as below:

AMGN' s Debt-to-Equity Range Over the Past 10 Years
Min: 1.12 Med: 2.9 Max: 10.64
Current: 10.37

During the past 13 years, the highest Debt-to-Equity Ratio of Amgen was 10.64. The lowest was 1.12. And the median was 2.90.

AMGN's Debt-to-Equity is ranked worse than
98.83% of 858 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs AMGN: 10.37

Amgen Debt-to-Equity Historical Data

The historical data trend for Amgen's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

3.09

3.51

4.97

10.64

10.37

Amgen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																10.64	11.52	9.08	7.90	10.37

Competitive Comparison

For the Drug Manufacturers - General subindustry, Amgen's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amgen Debt-to-Equity Distribution

For the Drug Manufacturers industry and Healthcare sector, Amgen's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Amgen's Debt-to-Equity falls into.

Amgen Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Amgen's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1443	+	63170)	/	6232
	=	10.37

Amgen's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1443	+	63170)	/	6232
	=	10.37

Amgen (NAS:AMGN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Amgen Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Amgen's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen (AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (NAS:AMGN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMG:Germany AMG:Germany AMG:Germany AMGN34:Brazil AMGN:Austria AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Executives

Nancy A. Grygiel	officer: SVP & CCO	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Jonathan P Graham	officer: SVP, Gen. Counsel & Secy.	2099 PENNSYLVANIA AVENUE, NW, 12TH FLOOR, WASHINGTON DC 20006
Matthew C. Busch	officer: VP, Finance & CAO	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Murdo Gordon	officer: EVP Global Commercial Ops	C/O BRISTOL-MYERS SQUIBB COMPANY, 345 PARK AVE, NEW YORK NY 10154
Rachna Khosla	officer: SVP, Business Development	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
R Sanders Williams	director	DUKE UNIVERSITY SCHOOL OF MEDICINE, TRENT DRIVE, DURHAM NC 27706
Robert Eckert	director	MATTEL, INC., 333 CONTINENTAL BLVD, M1-1518, EL SEGUNDO CA 90245
Michael V Drake	director	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Derek Miller	officer: SVP, Human Resources	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Omar Ishrak	director	710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Ronald D Sugar	director	10877 WILSHIRE BLVD., SUITE 1650, LOS ANGELES CA 900274
Linda H. Louie	officer: VP, Finance & CAO	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Amy E Miles	director
David Piacquad	officer: SVP, Business Development	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Peter H. Griffith	officer: EVP & CFO	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320